174 related articles for article (PubMed ID: 35119010)
41. Beyond the border: the use of lenvatinib in advanced hepatocellular carcinoma after different treatment lines: a retrospective analysis.
Jefremow A; Wiesmueller M; Rouse RA; Dietrich P; Kremer AE; Waldner MJ; Neurath MF; Siebler J
J Physiol Pharmacol; 2020 Oct; 71(5):. PubMed ID: 33571964
[TBL] [Abstract][Full Text] [Related]
42. Liver Function in Older Patients With Unresectable Hepatocellular Carcinoma After Administration of Lenvatinib.
Sasaki R; Fukushima M; Haraguchi M; Miuma S; Miyaaki H; Hidaka M; Eguchi S; Matsuo S; Matsuzaki T; Hashimoto S; Ohba K; Kugiyama Y; Yatsuhashi H; Shibata H; Motoyoshi Y; Shigeno M; Iwatsu S; Kato Y; Kinoshita N; Nakao K
Anticancer Res; 2021 Apr; 41(4):2025-2032. PubMed ID: 33813409
[TBL] [Abstract][Full Text] [Related]
43. Effectiveness of Lenvatinib Versus Sorafenib for Unresectable Hepatocellular Carcinoma in Patients with Hepatic Decompensation.
Park MK; Lee YB; Moon H; Choi NR; Kim MA; Jang H; Nam JY; Cho EJ; Lee JH; Yu SJ; Kim YJ; Yoon JH
Dig Dis Sci; 2022 Oct; 67(10):4939-4949. PubMed ID: 35048224
[TBL] [Abstract][Full Text] [Related]
44. Safety and efficacy of lenvatinib by starting dose based on body weight in patients with unresectable hepatocellular carcinoma in REFLECT.
Okusaka T; Ikeda K; Kudo M; Finn R; Qin S; Han KH; Cheng AL; Piscaglia F; Kobayashi M; Sung M; Chen M; Wyrwicz L; Yoon JH; Ren Z; Mody K; Dutcus C; Tamai T; Ren M; Hayato S; Kumada H
J Gastroenterol; 2021 Jun; 56(6):570-580. PubMed ID: 33948712
[TBL] [Abstract][Full Text] [Related]
45. Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma.
Finn RS; Ikeda M; Zhu AX; Sung MW; Baron AD; Kudo M; Okusaka T; Kobayashi M; Kumada H; Kaneko S; Pracht M; Mamontov K; Meyer T; Kubota T; Dutcus CE; Saito K; Siegel AB; Dubrovsky L; Mody K; Llovet JM
J Clin Oncol; 2020 Sep; 38(26):2960-2970. PubMed ID: 32716739
[TBL] [Abstract][Full Text] [Related]
46. Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study.
Chen S; Wu Z; Shi F; Mai Q; Wang L; Wang F; Zhuang W; Chen X; Chen H; Xu B; Lai J; Guo W
J Cancer Res Clin Oncol; 2022 Aug; 148(8):2115-2125. PubMed ID: 34453221
[TBL] [Abstract][Full Text] [Related]
47. Impact of Grip Strength in Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib.
Endo K; Kuroda H; Kanazawa J; Sato T; Fujiwara Y; Abe T; Sato H; Kooka Y; Oikawa T; Sawara K; Takikawa Y
Cancers (Basel); 2020 Aug; 12(8):. PubMed ID: 32756366
[TBL] [Abstract][Full Text] [Related]
48. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
[TBL] [Abstract][Full Text] [Related]
49. Therapeutic efficacy of lenvatinib for patients with unresectable hepatocellular carcinoma based on the middle-term outcome.
Fuchigami A; Imai Y; Uchida Y; Uchiya H; Fujii Y; Nakazawa M; Ando S; Sugawara K; Nakayama N; Tomiya T; Mochida S
PLoS One; 2020; 15(4):e0231427. PubMed ID: 32275701
[TBL] [Abstract][Full Text] [Related]
50. Reduction in Tumor Stain at 2 Weeks after Treatment Initiation Is a Predictor of the Efficacy of Lenvatinib in Patients with Unresectable Hepatocellular Carcinoma.
Kunimoto H; Shakado S; Tanaka T; Takata K; Yamauchi R; Fukuda H; Tsuchiya N; Yokoyama K; Morihara D; Takeyama Y; Hirai F; Sakisaka S
Oncology; 2020; 98(11):779-786. PubMed ID: 32877911
[TBL] [Abstract][Full Text] [Related]
51. Prognostic Advantages of Individual Additional Interventions After Lenvatinib Therapy in Patients with Advanced Hepatocellular Carcinoma.
Shindoh J; Kawamura Y; Kobayashi M; Akuta N; Okubo S; Matsumura M; Suzuki Y; Hashimoto M
J Gastrointest Surg; 2022 Aug; 26(8):1637-1646. PubMed ID: 35715641
[TBL] [Abstract][Full Text] [Related]
52. Risk Factors of Proteinuria in Patients with Hepatocellular Carcinoma Receiving Lenvatinib.
Ikesue H; Yamamoto H; Hirabatake M; Hashida T; Chung H; Inokuma T; Muroi N
Biol Pharm Bull; 2022; 45(3):333-338. PubMed ID: 35228399
[TBL] [Abstract][Full Text] [Related]
53. Adaptation of lenvatinib treatment in patients with hepatocellular carcinoma and portal vein tumor thrombosis.
Mukozu T; Nagai H; Matsui D; Mohri K; Watanabe G; Yoshimine N; Amanuma M; Kobayashi K; Ogino Y; Matsukiyo Y; Matsui T; Daido Y; Wakui N; Shinohara M; Momiyama K; Higai K; Igarashi Y
Cancer Chemother Pharmacol; 2022 Jan; 89(1):11-20. PubMed ID: 34628536
[TBL] [Abstract][Full Text] [Related]
54. Yttrium-90 radioembolization for hepatocellular carcinoma: Outcome prediction with MRI derived fat-free muscle area.
Faron A; Sprinkart AM; Pieper CC; Kuetting DLR; Fimmers R; Block W; Meyer C; Thomas D; Attenberger U; Luetkens JA
Eur J Radiol; 2020 Apr; 125():108889. PubMed ID: 32087468
[TBL] [Abstract][Full Text] [Related]
55. Factors Raising Serum Ammonia Level During Lenvatinib Treatment of Patients With Hepatocellular Carcinoma.
Narita R; Kotoh K; Yoneda A; Motomura M; Harada M
Anticancer Res; 2020 Sep; 40(9):5271-5276. PubMed ID: 32878816
[TBL] [Abstract][Full Text] [Related]
56. REFLECT-a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset.
Yamashita T; Kudo M; Ikeda K; Izumi N; Tateishi R; Ikeda M; Aikata H; Kawaguchi Y; Wada Y; Numata K; Inaba Y; Kuromatsu R; Kobayashi M; Okusaka T; Tamai T; Kitamura C; Saito K; Haruna K; Okita K; Kumada H
J Gastroenterol; 2020 Jan; 55(1):113-122. PubMed ID: 31720835
[TBL] [Abstract][Full Text] [Related]
57. Lenvatinib plus pembrolizumab for systemic therapy-naïve and -experienced unresectable hepatocellular carcinoma.
Wu CJ; Lee PC; Hung YW; Lee CJ; Chi CT; Lee IC; Hou MC; Huang YH
Cancer Immunol Immunother; 2022 Nov; 71(11):2631-2643. PubMed ID: 35347395
[TBL] [Abstract][Full Text] [Related]
58. Sarcopenia as a predictor of survival in patients undergoing bland transarterial embolization for unresectable hepatocellular carcinoma.
Lanza E; Masetti C; Messana G; Muglia R; Pugliese N; Ceriani R; Lleo de Nalda A; Rimassa L; Torzilli G; Poretti D; D'Antuono F; Politi LS; Pedicini V; Aghemo A;
PLoS One; 2020; 15(6):e0232371. PubMed ID: 32555707
[TBL] [Abstract][Full Text] [Related]
59. Real-world effectiveness of lenvatinib monotherapy in previously treated unresectable hepatocellular carcinoma in US clinical practice.
Singal AG; Nagar SP; Hitchens A; Davis KL; Iyer S
Cancer Rep (Hoboken); 2023 Jan; 6(1):e1679. PubMed ID: 35822407
[TBL] [Abstract][Full Text] [Related]
60. Lenvatinib combined with nivolumab in advanced hepatocellular carcinoma-real-world experience.
Wu WC; Lin TY; Chen MH; Hung YP; Liu CA; Lee RC; Huang YH; Chao Y; Chen SC
Invest New Drugs; 2022 Aug; 40(4):789-797. PubMed ID: 35477812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]